Commentary
Josep-Maria Ribera
Abstract
The anti CD19/CD3-bispecific T cell–engager monoclonal antibody blinatumomab is an effective drug with an acceptable toxic profile for the treatment of patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. This high efficacy has also been observed in patients with minimal residual disease. These favorable results have led to the investigation of the activity of this drug in early phases of the disease.